Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH

At the 10th European Stroke Organization (ESOC) conference, ACTICOR BIOTECH presented the results of its phase 2/3 study, ACTISAVE, focused on the treatment of acute ischemic stroke. On this occasion, Professor Martin Köhrmann reported that, although the main analysis of the effectiveness of glenzocimab did not reveal significant effects in the general population, positive trends were observed in some specific subgroups of patients.

Gilles Avenard, Managing Director, mentioned that these results encourage the company to continue its research to better understand the benefits of glenzocimab. In the same vein, the conference also made it possible to highlight the potential of the treatment in other studies, notably ACTIMIS, which shows a reduction in hemorrhagic transformations in certain patients.

The company plans to refine its strategies and continues discussions with pharmaceutical partners to support the future development of glenzocimab.